Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.815 -0.065 (-3.46%)
Streaming Delayed Price Updated: 1:30 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ProQR Announces Third Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
This First Solar Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗
 
Via Benzinga
News headline image
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
PRQR Stock Earnings: ProQR Therapeutics Beats EPS, Misses Revenue for Q2 2024 ↗
PRQR stock results show that ProQR Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
ProQR Announces Second Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
News headline image
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s session after the company announced a partnership with GCT Semiconductor to develop an RF module. Airspan... 
Via Benzinga
News headline image
US Stocks Lower; Dow Falls Over 50 Points ↗
U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday. Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13%... 
Via Benzinga
Topics Stocks
News headline image
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
News headline image
ProQR Announces Third Quarter 2023 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
From ProQR Therapeutics N.V.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.